Section of Plastic and Reconstructive Surgery, Department of Surgery, The University of Chicago, Chicago, Illinois.
Ann Surg. 2022 Oct 1;276(4):e255-e263. doi: 10.1097/SLA.0000000000004457. Epub 2020 Sep 1.
The aim of this study was to examine the long-term impact of physiologic surgical options, including VLNT and LVB, on patients with secondary lymphedema of the upper or lower extremity (UEL/LEL).
VLNT and LVB have become increasingly popular in the treatment of lymphedema. However, there is a paucity of long-term data on patient outcomes after use of these techniques to treat lymphedema.
An analysis of prospectively collected data on all patients who underwent physiologic surgical treatment of secondary lymphedema over a 5.5-year period was performed. Patient demographics, surgical details, subjective reported improvements, LLIS scores, and postoperative limb volume calculations were analyzed.
Two hundred seventy-four patients with secondary lymphedema (197 upper, 77 lower) were included in the study. More than 87% of UEL patients and 60% of LEL patients had reduction in excess limb volume postoperatively. At 3 months postoperatively, patients with UEL had a 31.1% reduction in volume difference between limbs, 33.9% at 6 months, 25.7% at 12 months, 47.4% at 24 months and 47.7% at 4 years. The reduction in limb volume difference followed a similar pattern but was overall lower for LEL patients. Greater than 86% of UEL and 75% of LEL patients also had improvement in LLIS scores postoperatively. Fifty-nine complications occurred (12.9%); flap survival was >99%.
Patients with secondary UEL/LEL who undergo VLNT/LVB demonstrate improved functional status and reduced affected limb volumes postoperatively. Patients with UEL seem to have a more substantial reduction in limb volume differential compared to LEL patients.
本研究旨在探讨包括 VLNT 和 LVB 在内的生理手术选择对上肢或下肢(UEL/LEL)继发性淋巴水肿患者的长期影响。
VLNT 和 LVB 在淋巴水肿的治疗中越来越受欢迎。然而,关于这些技术治疗淋巴水肿后患者结局的长期数据很少。
对 5.5 年内接受继发性淋巴水肿生理手术治疗的所有患者的前瞻性收集数据进行了分析。分析了患者人口统计学资料、手术细节、主观报告的改善、LLIS 评分以及术后肢体体积计算。
本研究纳入了 274 例继发性淋巴水肿患者(197 例上肢,77 例下肢)。超过 87%的 UEL 患者和 60%的 LEL 患者术后肢体多余体积减少。术后 3 个月,UEL 患者肢体体积差值减少 31.1%,6 个月减少 33.9%,12 个月减少 25.7%,24 个月减少 47.4%,4 年减少 47.7%。肢体体积差值的减少呈现出类似的模式,但 LEL 患者的总体减少幅度较低。超过 86%的 UEL 和 75%的 LEL 患者术后 LLIS 评分也有所改善。发生了 59 例并发症(12.9%);皮瓣存活率>99%。
接受 VLNT/LVB 治疗的继发性 UEL/LEL 患者术后功能状态改善,受累肢体体积减少。与 LEL 患者相比,UEL 患者肢体体积差异的减少更为显著。